A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19
Status:
Suspended
Trial end date:
2020-11-15
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy
and safety of axatilimab plus standard of care, compared with placebo plus standard of care,
in patients with respiratory signs and symptoms secondary to novel coronavirus disease
(COVID-19).